Volume 5, Issue 12

Using the New Biomarkers in Clinical Practice 

In this issue:

NfL — neurofilament light, from the blood, not the CSF. Is it a reliable indicator of MS activity, a predictor of relapse-related disability, and a monitor of treatment efficacy? OCT — optical coherence tomography. Fast, safe, reliable, and repeatable, it can reveal the cellular layers inside the retina. But how well does what OCT shows correlate with outcomes of importance in MS? And most important, how can these new biomarkers help clinicians care for their patients with MS now? 

Join us, as guest author Dr. Emily Schorr from the Department of Neurosciences at the University of California San Diego, addresses some of these questions in this issue of eMultipleSclerosis Review.

Learning objectives:

  • Describe the practical aspects of interpreting neurofilament light (NfL) for progression or treatment response in people with MS.

  • Describe the practical aspects of interpreting optical coherence tomography (OCT) for progression or treatment response in people with MS.

Author:

Emily Schorr, MD
Emily Schorr, MD

Assistant Professor of Neurosciences
University of California San Diego
La Jolla, CA

Program Directors:

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: December 5, 2023
Expiration date: December 4, 2025